Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that MET Exon 14 (Deletion) status confers therapeutic sensitivity to Capmatinib in patients with Non-Small Cell Lung Cancer.
The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.
This statement is based on a regulatory approval from the Food and Drug Administration:
TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.